Stockreport

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides [Yahoo! Finance]

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF Lacutamab was well-tolerated with a safety profile consistent with prior studies. Innate will host a virtual KOL event on Tuesday, June 11, 2024 at 4:00PM CEST (10:00A [Read more]